Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses
  • Ocular DB

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Global Health DermatologyOral presentationsGD01 Comparative efficacy of Mycobacterium indicus pranii and bacille Calmette–Guérin as immunotherapeutic adjuncts in multibacillary leprosy: a clinical and molecular randomized controlled trial

Jain S, Chhabra S, Dogra S, et al. Oxford University Press (OUP). British Journal of Dermatology. 2024;
Publication

Changes in the Cutaneous Nerve Fiber Staining and Distribution of PGP9.5 in Clinically Uninvolved Skin in Leprosy Patients after Completion of Multidrug Therapy and Assessing PGP9.5 as a Marker of Treatment Response

Thakur V, Narang T, Bishnoi A, et al. Medknow. Indian Dermatology Online Journal. 2024; 15 (4) : 599-604.
Download PDF
Publication

Borderline leprosy with unilateral blepharoptosis in reversal reaction

Palaniappan V, Raveendran P, Karthikeyan K. Medknow. Oman Journal of Ophthalmology. 2024; 17 (2) : 299-300.
Download PDF
Publication

A case report on imaging findings of rare segmental necrotizing granulomatous neuritis of leprosy involving ulnar nerve.

Netam S, Gupta N, Chandrakar N. Qatar medical journal. 2024; 2024 (3) : 1-7.
Download PDF
Publication

Central Serous Chorioretinopathy in a Patient with Hansen’s Disease with Type 1 Lepra Reaction - A Case Report

Singh T, Narang T, Yakang D. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Morbimortalidade por Reações em Hanseníase

Ribeiro Filha Coriolano C. Universidade de Brasília. Faculdade de Ciências da Saúde. 2021;
Download PDF
Publication

Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR)

Penna GO, Pontes MADA, Talhari S, et al. Elsevier BV. The Brazilian Journal of Infectious Diseases. 2024; 28 (2) : 1-8.
Download PDF
Publication

Associação do poliformismo rs2228570 no gene VDR com o desfecho terapêutico em hanseníase

Gasparini Bernardes B. Instituto Lauro de Souza Lima . Secretaria de Estado da Saúde de São Paulo. 2024;
Download PDF
Publication

A Cross-Sectional Study of the Success of the Leprosy Elimination Strategy before and after a 10-Year Eradication Period in a Referral Hospital in Tamil Nadu, India

Sundaramoorthy A, Hemachandran K, Abilash VG, et al. B P International. Medical Research and Its Applications Vol. 6. 2024;
Publication

Erythema nodosum leprosum necroticans: a case report of an atypical severe type 2 leprosy reaction and literature review.

Alfieri A, Dewi S, Siswati A, et al. Le infezioni in medicina. 2024; 32 (2) : 248-253.
Download PDF

Pagination

  • Previous page ‹‹
  • Page 10
  • Next page ››
Subscribe to Multi-drug therapy (MDT)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

© 2025 InfoNTD